# Derlend Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/derlend-biotech

- Industry: Medical Devices & Equipment
- Headquarters: Hangzhou, China
- Latest round: Series A (Jul 27, 2023)
- Investors on record: 4

## About

Established in 2012 and based in Hangzhou, China, Derlend Biotech is a medical device's company specializing in the independent development, production, sales, and service of in vitro diagnostic reagent products. The company owns 3 invention patents and has obtained 3 registration certificates for fungal nucleic acid detection kits for Class III IVD products from the State Drug Administration. In July 2023, Derlend Biotech raised series A+ funding from new investors Jin Sheng Group and PKU Collaborative Venture.

The company's main business is the research and development, production and sales of in vitro diagnostic reagent products. The company's mainly products include fungal nucleic acid detection kit series, fungal nucleic acid extraction and purification kit series, fungal immunofluorescence staining solution series and other in vitro diagnostic reagent products.

## Funding rounds

- Series A, Jul 27, 2023 — PKU Collaborative Venture, Hangzhou Jinsheng Group
- Series A, Aug 5, 2022 — Cybernaut Investment Group, Zhejiang Zhongying Holding Group

## Investors

- Cybernaut Investment Group (https://capitalatlas.ai/funds/cybernaut-investment-group) — Series A
- Zhejiang Zhongying Holding Group — Series A
- PKU Collaborative Venture (https://capitalatlas.ai/funds/pku-collaborative-venture) — Series A
- Hangzhou Jinsheng Group — Series A